Prevent Breast Cancer’s Achievements

Prevent Breast Cancer work with internationally renowned scientists to try and prevent breast cancer. Here are our achievements to date.

  • Between August 2015 and September 2017, over 100 research papers were published by our scientists.
  • Professor Gareth Evans has begun trials in Greater Manchester, which will see breast screening tailored to individual risk for the first time on the NHS, a new approach that could revolutionise breast screening across the UK.
  • Our researchers have identified gene fragments which increase the risk of the disease, even where no family history is present.
  • We’re leading the way when it comes to investigating the strong links between cancer and breast density.
  • Preventative drugs that may stop the spread of breast cancer or even prevent it appearing altogether have been identified by our scientists.
  • Around a quarter of breast cancer cases are thought to be caused by lifestyle choices, which is why we are researching how best to offer dietary advice as part of the NHS breast screening programme.
  • In the past 12 months we have appeared in over 700 pieces of media coverage, including The Times, Daily Telegraph, Daily Mail, The Sun and ITV’s Lorraine.
  • Our Scientific Directors were part of a group of 10 experts who met to draw up a “Gap Analysis” of our knowledge concerning breast cancer and breast biology. Risk determination and prevention were identified as major gaps and the resulting paper, which was published in “Breast Cancer Research” in September 2014, was one of the two most accessed papers in the journal last year.
  • The other most accessed paper in “Breast Cancer Research” was written by Prevent Breast Cancer Professor, Gareth Evans. “The Angelina Effect” described how referrals to our own and other Family History Clinics and Genetic Centres doubled. This was a result of publicity surrounding Angelina Jolie’s decision to have risk-reducing breast surgery after the discovery that she carries a mutation in the BRCA1 gene. Most of the referrals were judged to be appropriate indicating an unfulfilled need for services for women at a very high risk. The paper had the highest Altmetric score for any paper ever published by the journal.
  • Over 57,000 women were recruited to The PROCAS Study. This amounts to approximately 40% of the total women who attended screening in Greater Manchester between 2009 and 2015.
  • Our Risk Communication Feedback Study, looked at how risk should be communicated to women within The PROCAS study. The outcomes from this research helped to provide an effective communications strategy that should guide the implementation of breast cancer risk information to the National Breast Screening Programme.
  • Publication of The 2-Day Diet, Cookbook and Quick & Easy edition continues to increase awareness of our vital work and send a positive health message across the UK and the world. To date over 340,000 copies have sold in the UK and the diet was published in over 16 countries.
  • Recent proceeds from the book sales have enabled Prevent Breast Cancer to fund the BRRIDE-2 study which is analysing the effect of an intermittent diet (The 2-Day Diet) versus a daily energy restriction diet on body fat stores and blood markers associated with breast cancer risk.
  • Our research has shown that Anastrozole can reduce breast cancer risk by over 50%.
  • Prevent Breast Cancer showed its commitment to supporting the next generation of clinical researchers by collaborating with The Association of Breast Surgery (ABS). We will award grants of up to £3,000 per year, which will be matched by The ABS and will support the work of young surgeons by funding the early stages of their research under the supervision of world-renowned experts.
  • Since 2001 we have funded the first UK dietitian for prevention of breast cancer, Dr Michelle Harvie.
  • We have demonstrated that regular MR scans are effective in young high-risk women, a policy now adopted in NICE guidelines.
  • We have demonstrated that hormone altering tablets such as tamoxifen, raloxifene and Aromatase inhibitors are effective in lowering breast cancer risk in selected women, a policy now adopted in NICE guidelines.

Please click here to read about our research strategy and current research projects.